James Cropper FY26 slides: EBITDA jumps 33%, debt falls sharply

This is primarily a balance-sheet rerating story, not a clean demand inflection. The market is paying up for the combination of positive cash conversion, lower leverage, and refinancing optionality, because those three variables reduce the probability of an equity dilutive event and can justify a higher multiple even if reported growth stays modest. The hidden risk is that the current free-cash-flow profile is flattered by working-capital release and unusually low capex; once maintenance and debottlenecking spend normalizes, the equity story can look much less linear.

The only clear external winner is HSBC, but the benefit is incremental rather than earnings-changing: asset-backed finance exposure to a de-risking borrower improves credit optics and slightly supports fee income. More interesting second-order effects sit in the supply chain: better utilization and service levels at a niche paper/packaging operator can pressure weaker regional converters that lack pricing power, while the advanced materials arm remains a call option on hydrogen/electrolysis capex rather than a durable near-term growth engine. If that end market stalls, FY27 could look like a digestion year rather than a continuation.

Consensus appears to be underpricing how quickly the rerating can reverse if the balance sheet stops improving. A move back above roughly 1.5x net debt to EBITDA, or a reversion to losses in paper/packaging, would undermine the turnaround narrative and likely compress the multiple fast. Time horizon matters: the next 1-3 months are about order book and guidance quality; the next 6-18 months are about whether capex and mix improvements convert into structurally higher cash earnings, or just a one-year rebound.